Analyst recommendations

The biotechnology sector has been incredibly successful in 2014 year. Its growth outperformed the growth of S&P 500  stunning 36%. Analysts at JP Morgan believe that a huge priority sector dynamics can decrease in 2015 year, but may remain the same level. The main drivers the success of biotech in 2014 were a high demand for the main products of the sector, the positive results of many clinical studies phase a wave of successful initial public offerings.
Date Company Who recommends Recommendation Target price
Thermo Fisher Scientific, Inc. Argus Buy 145
Express Scripts Holding Company RBC Capital Mkts Buy 95
Johnson & Johnson Deutsche Bank Buy 105
Regeneron Pharmaceuticals, Inc. Barclays Buy 593
Endo International plc Deutsche Bank Buy 88
Eli Lilly and Company BofA/Merrill Buy 90
Mylan N.V. Barclays Buy 57
Waters Corporation BofA/Merrill Buy 140
UnitedHealth Group Incorporated Morgan Stanley Buy 140
Aetna Inc. BofA/Merrill Buy 162
Humana Inc. Barclays Buy 223
Celgene Corporation UBS Buy 156
Becton, Dickinson and Company Deutsche Bank Buy 167
Cigna Corp. Barclays Buy 156
CVS Health Corporation Deutsche Bank Buy 118
Alexion Pharmaceuticals, Inc. UBS Buy 223
Intuitive Surgical, Inc. Barclays Buy 625
PerkinElmer Inc. UBS Buy 60
1 2